Atomo Diagnostics

Executive Summary

Atomo Diagnostics is an Australian med-tech company specializing in user-centric rapid diagnostic test (RDT) platforms, with its proprietary AtomoRapid™ devices designed to minimize user error by integrating sample collection and fluid handling. The company targets infectious diseases, sexual health, and women’s health, delivering lab-equivalent performance at the point of care. Founded in 2010 and now in the commercial stage, Atomo has established a strong foothold in global markets, particularly for HIV self-testing, where its products are used in over 50 countries. The company’s innovative design simplifies testing workflows, enabling reliable results even for untrained users, which is critical for expanding access to diagnostics in low-resource settings. Atomo continues to diversify its pipeline, developing RDTs for other infectious diseases such as malaria and dengue, as well as expanding into women’s health with pregnancy and fertility tests. With a growing emphasis on decentralized testing and self-care, Atomo is well-positioned to capture market share. However, as a private company, financial details are limited. Key upcoming catalysts include potential FDA clearance for its HIV self-test in the US market, new product launches in emerging markets, and strategic partnerships with global health organizations to scale distribution. These events could significantly accelerate revenue growth and validate its platform technology.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for AtomoRapid HIV Self-Test70% success
• Q2 2027Launch of AtomoRapid Multiplex (HIV/Syphilis) Test in Africa65% success
• Q3 2026Partnership with UNITAID or similar global health funder for large-scale procurement55% success